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Abstract  T2*-weighted  perfusion  MRI  is  based  on  the  so-called  ‘‘ﬁrst  passage’’  approach:  the
modiﬁcations  in  the  T2-weighted  MRI  signal  are  followed  during  the  ﬁrst  passage  of  a  bolus
of contrast  agent.  The  pixel-by-pixel  analysis  of  the  curves  is  used  to  obtain  parametric  maps
(time of  arrival,  time  of  the  peak,  mean  transit  time,  relative  volume  and  blood  ﬂow).  Further
analysis, with  deconvolution  by  arterial  input  function  (concentration  of  contrast  agent  in  theMean  transit  time blood), helps  improve  the  quantiﬁcation.  It  is  possible  to  pre-inject  a  small  dose  of  contrast
agent to  limit  the  impact  of  the  extravasation  of  the  contrast  agent.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Perfusion  imaging  includes  a great  many  methods.  In  fact,  the  perfusion  may  be  character-
ized  by  a  great  many  parameters.  In  addition,  these  parameters  may  be  obtained  in  several
ways.  In  this  article,  the  authors  deal  with  perfusion  MR  imaging  and,  more  particularly,
the  methods  based  on  T2*-weighted  variations.
Generalities
Parameters characteristic of perfusion
The  three  main  physiological  quantities  characterizing  the  perfusion  and  accessible  with
T2*-weighted  perfusion  MRI  are:
• the  tissue  blood  volume  or  blood  volume  fraction.  In  general,  the  blood  volume  isexpressed  in  mL  of  blood  per  100  g  (or  100  mL)  of  tissue  (mL/100  g).  The  blood  vol-
ume  fraction,  corresponding  to  the  relationship  between  the  blood  volume  (in  mL)  and
the  tissue  volume  (in  mL)  is  expressed  in  %;
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the  tissue  blood  ﬂow  or  volume  of  blood  circulating  in
a  voxel  per  unit  of  time.  In  general,  it  is  expressed  in
mL  of  blood  per  100  g  (or  100  mL)  of  tissue  and  for  1  min
(mL/100  g/min);
the  mean  transit  time  (MTT);  the  blood  volume  and  blood
ﬂow  in  a  voxel  are  mathematically  related  through  the
value  of  the  MTT  (central  volume  theorem).
ontrast agent
2*-weighted  perfusion  imaging  is  based  on  the  use  of  a
racer,  a  paramagnetic  contrast  agent,  injected  in  the  blood
irculation.  A  tracer  should  act  like  the  element  to  be  char-
cterized  —  in  general  plasma.  It  should  be  detectable  by
he  imaging  method  and  should  not  disturb  the  circulation
f  the  blood  [low  volume  injected,  no  arterial  overpressure
t  the  time  of  injection,  no  interaction  between  the  tracer
nd  the  components  in  the  blood  (inert  molecule),  etc.].
 tracer  does  not  allow  for  the  overall  characterization  of
he  blood:  plasma  and  erythrocytes  take  up  different  vol-
me  fractions  and  circulate  at  different  speeds.  In  perfusion
maging,  the  terms  ‘‘tracer’’  and  ‘‘contrast  agent’’  are  used
ndifferently.
To  obtain  perfusion  imaging,  a  non-diffusible  tracer  is
ecessary,  that  is,  a  tracer  that  does  not  cross  the  walls  of
he  vessels.  In  general,  the  ability  of  a  tracer  to  extravasate
epends  on  its  size,  which  can  be  determined  by  the  molec-
lar  weight  (in  Da)  or  by  the  apparent  molecular  size  (in
m)  still  called  hydrodynamic  diameter,  its  hydrophilic  or
ipophilic  nature  or  its  electrical  charge.  Of  course,  the  same
ontrast  agent  may  extravasate  in  one  organ  and  not  in
nother  (for  example,  a  Gd  chelate  does  not  extravasate
n  the  brain  but  does  so  in  the  muscle).
oxel model
 voxel  model  is  used  for  the  ﬁrst  passage  method.  It  com-
rises  a  single  arterial  input  and  a  single  venous  output.  The
nput  and  the  output  are  connected  by  a  network  comprising
 great  many  capillaries.
At  time  t,  the  concentrations  in  tracer  at  the  arterial
nput  and  the  venous  output  are  represented  by  Ca(t)  and
v(t),  respectively.  The  mean  concentration  in  tracer  is
oted  in  the  voxel  Cvoxel(t).  This  model  does  not  apply  to
ll  tissues  (the  liver  comprises  two  vascular  inputs).
The  blood  ﬂow,  F,  at  the  arterial  input,  should  be  the
ame  as  the  blood  ﬂow  at  the  venous  output  (if  not,  the
lood  will  accumulate  in  the  voxel).
Between  arterial  input  and  the  venous  output,  the  blood
as  a  set  of  possible  pathways  that  are  characterized  by  dif-
erent  lengths.  Tracer  molecules  reaching  the  arterial  input
t  the  same  time  will  require  different  times  to  cross  this
oxel.  This  distribution  of  transit  times  is  an  important  char-
cteristic  of  the  microvascular  network  of  the  voxel.
erfusion imaging methodsynamic methods and steady-state methods
wo  approaches  are  used  to  obtain  information  about
he  perfusion.  Either  images  are  obtained  on  a regular
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asis  during  the  passage  of  the  contrast  product  in  the
one  of  interest  (‘‘dynamic’’  approach),  or  an  image  is
btained  before  and  after  the  injection  of  a contrast  prod-
ct  (‘‘steady-state’’  approach).  The  dynamic  approach  is
sed  in  almost  all  cases,  in  the  absence  of  contrast  agents
hat  are  adapted  for  and  authorized  in  man.  In  addition,  the
ynamic  method  provides  the  most  information.
he so-called ‘‘ﬁrst passage’’ method
irst  passage  information
he  method  consists  of  measuring  variations  in  signal  dur-
ng  the  ﬁrst  passage  of  a non-diffusible  contrast  agent.  This
rinciple  was  introduced  in  1824  by  Hering  as  the  ‘‘indicator
ilution  method’’  [1].
To  understand  the  ﬁrst  passage  concept,  it  is  necessary
o  imagine  the  circulation  of  the  blood  in  the  body  as  a
et  of  loops  that  go  from  the  heart  to  an  organ.  When  a
ontrast  product  is  injected  in  the  vein  of  an  arm,  the  prod-
ct  reaches  the  heart,  crosses  the  lungs  and  returns  to  the
eart  before  exiting  by  the  aorta.  All  the  organs  or  parts  of
he  body  receive  the  contrast  product  by  their  arteries.  The
oncentration  of  the  arterial  input  will  be  approximately
he  same  in  each  organ.  The  contrast  product  crosses  each
rgan  —  this  is  the  ﬁrst  passage  —  before  returning  to  the
eart.  The  return  of  the  tracer  to  the  heart  via  the  different
oops  occurs  in  disorder,  as  the  time  taken  by  the  tracer  to
omplete  a  loop  is  variable.  A  second  passage  of  the  bolus
f  the  tracer  is  sometimes  visible  in  the  organs,  before  the
ontrast  product  is  diluted  in  the  entire  blood  circulation.
his  second  passage  may  be  visible  before  the  end  of  the
rst  passage  (as  is  the  case  in  the  brain,  for  example).
In  the  ﬁrst  passage  experiment,  we  assume  that  we  only
easure  the  ﬁrst  passage  (no  recirculation).  To  come  close
o  it,  the  injection  of  product  has  to  be  as  brief  as  possi-
le.  Since,  in  practice,  recirculation  occurs  (the  circulation
f  blood  is  fortunately  a  closed  circuit),  it  is  necessary  to
xtract  the  ﬁrst  passage  data  during  the  analysis.  For  this,
he  data  measured  is  adjusted  by  the  derivative  of  the
amma  function  (empirical  discovery  [2]):
voxel (t) = K(t  −  t0)˛ exp [− (t −  t0) /ˇ] (1)
here  K,  ˛  and  ˇ  are  parameters  without  biological  signif-
cance  and  where  t0 represents  the  time  of  arrival  of  the
racer  at  the  voxel.  The  equation  (1)  adjusted  to  the  data
epresents  the  ﬁrst  passage  for  each  pixel.  Now  that  we
ave  extracted  the  ﬁrst  passage  information,  we  will  see
ow  to  extract  the  relative  and  then  quantitative  perfusion
haracteristics.
‘Qualitative’’  analysis
t  is  fairly  direct  to  obtain  a  value  for  the  blood  volume
raction  in  the  voxel.  The  mean  concentration  in  tracer  in
he  voxel,  Cvoxel(t),  equals  [3]:
voxel (t) = vpCp (t) (2)
here  Cp(t)  represents  the  mean  concentration  in  tracer  in
he  plasma  of  the  voxel  and  vp the  volume  fraction  of  the
lasma  in  the  voxel.  Note  that  the  form  of  Cp(t)  and  Ca(t)  is
ot  the  same  due  to  the  distribution  of  transit  times  in  the
oxel.  Nevertheless,  in  view  of  the  principle  of  conservation
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of  matter,  and  given  that  the  tracer  is  not  diffusible,  the
total  quantity  of  tracer  that  passes  through  the  artery  should
pass  through  the  blood  of  the  voxel.  This  equality  of  quantity
is  represented  by:
∞∫
0
Cp (t)  (Fdt) =
∞∫
0
Ca (t)  (Fdt) (3)
In  this  equation,  Fdt  represents  the  elementary  volume
of  blood  and  C(t)Fdt  represents  an  elementary  volume  of
tracer.  By  using  equations  (2)  and  (3),  it  is  now  possible  to
calculate  vp:
vp =
∞∫
0
Cvoxel (t)dt
∞∫
0
Ca (t)dt
= Area − under − the − curve Cvoxel (t)
Area − under − the − curve Ca (t) (4)
Assuming  that  Ca(t)  —  the  arterial  input  function  —  is
the  same  for  all  of  the  voxels  in  the  organ  considered,  we
note  that  vp is  proportional  to  the  area  under  the  curve
‘‘concentration  in  contrast  agent  in  the  voxel  as  a  function
of  time’’.  To  obtain  a  quantitative  value  for  vp,  it  is  neces-
sary  to  also  quantitatively  determine  the  values  of  Cvoxel(t)
and  Ca(t)  (see  further  down).  If  we  only  have  absolute  pixel-
by-pixel  values  of  Cvoxel(t),  it  is  still  possible  to  obtain  a  map
of  the  relative  plasma  volume  fractions.  This  highly  useful
map  is  used  to  calculate  a  relationship  between  the  plasma
volume  fraction  measured  in  a  region  of  interest  and  that
measured  in  a  reference  region.
Analysis  of  the  ﬁrst  passage  curve  thereby  allows  for  an
estimate  —  at  least  a  relative  estimate  —  of  vp.  However,
it  is  possible  to  go  farther.  On  the  basis  of  the  ﬁrst  passage
curve,  it’s  also  possible  to  obtain  information  about  the  MTT
of  the  plasma  in  the  voxel.  The  microvascular  network  of
the  model  voxel  may  be  described  by  the  distribution  of  its
transit  times.  The  fraction  of  the  tracer  molecules  with  a
transit  time  t  to  cross  the  voxel  is  noted  as  h(t).  The  sum  of
the  fractions  of  molecules  with  a  transit  time  through  the
voxel  ranging  from  0  to  inﬁnity  is  necessarily  1  (that  is,  all
of  the  molecules).  This  is  noted  as:
∞∫
0
h (t)dt =  1  (5)
It  is  therefore  possible  to  mathematically  deﬁne  the  MTT
as  the  mean  value  of  the  distribution  h(t):
∞∫
0
th (t)dtMTT  = ∞∫
0
h (t)dt
− t (6) v
i
s
s1207
In  practice,  the  relative  value  of  the  MTT  is  obtained  from
voxel(t)  by  calculating:
TT  =
∞∫
0
tCvoxel (t)dt
∞∫
0
Cvoxel (t)dt
−  t0 (7)
here  t0 is  the  time  for  the  arrival  of  the  tracer  in  the  voxel
refer  to  equation  (1)].
Now  that  we  have  the  values  for  the  relative  blood  vol-
me  and  MTT,  let’s  see  how  to  obtain  a  value  for  the  relative
lood  ﬂow  (F)  from  the  ﬁrst  passage  curve.  If  h(t)  is  the  frac-
ion  of  molecules  that  take  a  time  t  to  cross  the  voxel,  then
Fh(t)  is  the  fraction  of  the  blood  volume  (tF  is  a  volume
raction)  that  takes  time  t  to  cross  the  voxel.  From  equation
6), we  thereby  obtain  [4]:
p =  F
∞∫
0
th (t)dt =  F  ×  MTT  (8)
The  relationship  between  is  called  the  central  volume
heorem.  It  allows  for  an  estimate  of  F.
uantitative  analysis
o  obtain  the  quantitative  values  of  vp and  F,  we  determine
he  quantity  of  tracer  that  remains  in  the  voxel  following
he  instantaneous  input  of  tracer:
(t) = 1  −
t∫
0
h (t)dt (9)
The  R(t)  function  is  called  the  residue  function.  R(0)  =  1:
t  t  =  0,  nothing  has  left  the  voxel  (the  time  of  arrival  is  con-
idered  to  be  zero  here),  then  the  value  of  R(t)  decreases  as
he  tracer  leaves  the  voxel.  Using  equations  (9)  and  (10),  the
oncentration  in  tracer  in  the  voxel  may  now  be  calculated:
voxel (t) = FCa (t) ⊗  R (t) = F
t∫
0
Ca ()R (t −  )d  (10)
Equation  (10)  indicates  that,  to  quantitatively  obtain  F
nd  vp, a  deconvolution  of  Cvoxel(t)  is  required  by  Ca(t),
hich  means  estimating  the  residue  function.  This  process
s  complex.  Certain  approaches  use  a  model  function  for  the
esidue  function  [5]. This  deconvolution  also  has  to  be  ren-
ered  insensitive  to  the  value  of  the  arrival  time,  t0 [6].  If
his  is  not  the  case,  the  variations  in  arrival  time  result  in
ariations  in  the  estimates  of  the  perfusion  parameters.
he steady-state approach
ith  non-diffusible  tracers  and  slow  clearance  (long  plasma
alf-life),  it  is  possible  to  obtain  an  estimate  of  the  blood
olume  and  an  approach  to  the  mean  diameter  of  the  vessels
n  the  voxel  by  means  of  MRI.  This  approach  is  MRI-speciﬁc,
ince  it  is  in  part  based  on  the  fact  that  the  MRI  signal  is
ensitive  to  the  diffusion  of  water  [7].  This  steady-state
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pproach  has  the  advantage  of  producing  maps  with  excep-
ional  spatial  resolution  that  are  easy  to  quantify  [8].
ink between MRI signal and contrast
gent
ffects of contrast agents on the MRI signal
he  contrast  agents  used  in  clinical  MRI  are  not  directly
etectable,  as  opposed  to  other  means  of  imaging.  Their
resence  is  detected  indirectly  through  the  effects  that  they
nduce  on  the  MRI  signal  of  water.  The  effects  of  relaxivity
nd  susceptibility  are  distinguished.
ffects  of  relaxivity
he  MRI  contrast  agents  catalyze  the  relaxation  phenomena:
n  the  presence  of  contrast  agent,  the  longitudinal  relax-
tions  —  characterized  by  R1 =  1/T1 —  and  transverse
elaxations  —  characterized  by  R2 =  1/T2 —  occur  more
uickly  (R1 and  R2 increase).  This  increase  linearly  depends
n  the  concentration:
1 =  R1,0 +  r1 [Gd] (11a)
2 =  R2,0 +  r2 [Gd] (11b)
here  R1,0 and  R2,0 represent  the  speed  of  relaxation  in
he  absence  of  contrast  agent  and  are  characteristics  that
epend  on  the  contrast  agent,  the  magnetic  ﬁeld  and  the
emperature.  [Gd]  represents  the  concentration  in  contrast
gent.
If  the  contrast  agent  is  intravascular  (non-diffusible),
hen  the  T1 and  T2 of  the  blood  are  reduced.  However,
ue  to  the  exchange  of  water  occurring  through  the  walls
f  the  vessels,  T1 and  T2 of  the  extravascular  space  may
lso  be  slightly  reduced,  while  the  contrast  agent  has  not
enetrated  in  the  interstitial  space.
ffects  of  magnetic  susceptibility
ll  of  the  bodies  magnetize  when  placed  in  a  magnetic
eld.  The  intensity  of  this  magnetization  is  characterized
y  the  magnetic  susceptibility  of  the  body.  Thereby,  a  con-
rast  agent  has  a  magnetic  susceptibility:  gadolinium  chelate
Gd)  are  paramagnetic,  the  particles  of  iron  oxide  are  super-
aramagnetic.  Without  contrast  agent,  the  magnetization
f  the  blood  differs  from  that  of  the  surrounding  tissue.
he  presence  of  a  contrast  agent  in  the  vessels  consider-
bly  reinforces  this  difference  in  the  magnetization  between
he  intravascular  and  extravascular  compartments.  Between
hese  two  compartments,  there  is  a  variable  gradient  in
agnetic  ﬁeld.  The  variation  in  the  heterogeneity  of  the
ntensity  of  the  magnetic  ﬁeld  in  the  voxel  leads  to  a varia-
ion  in  the  T2*  of  the  voxel.
irst passage monitoring
d  is  the  contrast  agent  most  often  used.  The  molecular
eight  is  about  500  Da  (variable  according  to  the  manu-
acturer).  The  presence  of  contrast  agent  simultaneously
nduces  effects  on  T1,  T2 and  T2*.  T2*-weighted  sequences
re  almost  only  used,  although  certain  tests  have  been
p
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arried  out  with  T2-weighted  sequences  and  more  recently
1-weighted  sequences  (in  particular  with  spiral  imaging
hat  allows  for  very  short  echo  times,  thereby  being  little
ensitive  to  variations  in  T2*).  The  choice  to  employ  the  T2*
ffect  is  based  on  two  main  reasons:
the  effect  is  approximately  independent  of  the  size  of  the
vessels  (which  is  not  the  case  for  the  effect  on  T2 [9]);
the  T2*  effect  results  in  higher  variations  in  signal  than
the  T2 or  T1 effects.
easurement  of  the  tracer  concentration  in  the
oxel
ifferent  studies  have  analyzed  the  relationship  between
he  concentration  of  contrast  agent  in  the  voxel  and  the  vari-
tion  in  relaxation  speed  (noted  R∗2 =  1/T∗2 ).  It  is  generally
ccepted  that  [9]:
voxel (t) ∞ R∗2 (t) −  R∗2,0 =  R∗2 (t) (12)
here  R∗2,0 represents  the  speed  of  relaxation  of  the  base
ine  (in  the  absence  of  Gd).  If  a gradient  echo  is  repeatedly
cquired  —  for  example  with  an  echo  planar  sequence  (EPI)
 during  the  passage  of  the  bolus,  for  each  pixel  it  is  possible
o  calculate:
R∗2 (t) =
1
TE
ln
(
S (t)
S0
)
(13)
here  TE  represents  the  echo  time,  S0 the  signal  of  the  base
ine  (average  of  several  measurements)  and  S(t)  the  signal
s  a  function  of  time.  By  analyzing  the  shift  in  time  of  each
ixel  (that  is,  R∗2 (t)),  we  obtain  parametric  maps.
easurement  of  the  arterial  input  function
he  relationship  between  signal  of  the  voxel  and  concentra-
ion  in  contrast  agent  does  not  apply  to  the  signal  coming
rom  the  vessels.  In  fact,  if  the  concentration  in  contrast
gent  is  too  high,  the  linear  relationship  provided  by  the
quation  (12)  is  no  longer  valid  [10,11].  However,  for  vox-
ls  located  near  an  artery  in  the  magnetic  ﬁeld  gradient
etween  vessels  and  surrounding  tissue,  we  observe  a  linear
elationship  between  the  tracer  concentration  in  the  artery
nd  (R∗2) [12]. Therefore,  these  voxels  have  to  be  used  in
rder  to  obtain  an  estimate  of  the  arterial  input  function.
onclusion
he  T2*-weighted  perfusion  MRI  is  based  on  the  dynamic
haracterization  of  the  ﬁrst  passage  of  an  exogenous  con-
rast  agent.
Although  the  theoretical  basis  of  this  method  has  been
ell  established,  the  quantiﬁcation  of  the  parameters
emains  difﬁcult.  In  fact,  the  effects  of  relaxivity  and
usceptibility  related  to  the  presence  of  the  contrast
gent  in  a  compartment  are  complex.  More  generally,  a
tandard  acquisition  protocol,  or  recognized  processing  soft-
are  is  not  available  (even  if  the  different  manufacturers
ropose  software  solutions),  which  also  raises  problems.
ecently,  Willats  and  Calamante  proposed  a  strategy  for
he  processing  of  T2*-weighted  perfusion  data  in  order  to
tandardize  the  practice  [13].
[[
[T2-*weighted  perfusion  MRI  
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